Inclusion Criteria:

1. Biopsy-proven diagnosis of low-grade Non-Hodgkin's follicular lymphoma of the orbit
or MALT of the conjunctiva/orbit. The orbit/conjunctiva has to be the primary or
predominant site of involvement or if there is a previous history of systemic
involvement, the orbit/conjunctiva should be the only site of new recurrence.

2. No anti-cancer therapy for three weeks (six weeks if Rituximab, nitrosourea or
Mitomycin C) prior to study initiation, and fully recovered from all toxicities
associated with prior surgery, radiation treatments, chemotherapy, or immunotherapy

3. An IRB-approved signed informed consent

4. Age >18 years. This is justified since low-grade non-Hodgkin's lymphoma of the orbit
is extremely rare to non-existent in the pediatric population

5. Expected survival of >3 months

6. Pre-study performance status of 0, 1, or 2 according to the WHO

7. Acceptable hematologic status within two weeks prior to patient registration,
including: a) Absolute neutrophil count ([segmented neutrophils + bands] x total
WBC)> 1500/mm3 b) Total lymphocyte count < 5,000/mm3 for patients with small
lymphocytic lymphoma (IWFA) c) Platelet counts> 150,000/mm3, these patients will
receive a dose of 0.4 mCi/kg of Zevalin d) Platelet counts from 100,00/mm3 to
149,000/mm3, these patients will receive a 0.3mCi/kg dose of Zevalin

8. Female patients who are not pregnant or lactating

9. Men and women of reproductive potential who are following accepted birth control
methods (as determined by the treating physician, however abstinence is not an
acceptable method)

10. Patients previously on Phase II drugs are eligible if no long-term toxicity is
expected, and the patient has been off the drug for eight or more weeks with no
significant post treatment toxicities observed

11. Patients determined to have less than 25% bone marrow involvement with lymphoma
within six weeks of registration (based on a bone marrow biopsy). (This criteria must
be strictly met for adequate patient safety.)

Exclusion Criteria:

1. Patients with impaired bone marrow reserve, as indicated by one or more of the
following: a) Prior myeloablative therapies with autologous bone marrow
transplantation (ABMT) or peripheral blood stem cell (PBSC) rescue b) Platelet count
< than 100,000 cells/mm3 c) Hypocellular bone marrow (less than 15% cellularity) d)
Marked reduction in bone marrow precursors of one or more cell lines (granulocytic,
megakaryocytic, erythroid)

2. Prior radioimmunotherapy

3. Presence of CNS lymphoma

4. Patients with HIV or AIDS-related lymphoma

5. Patients with small lymphocytic lymphoma (IWF A) - who have a total lymphocyte count
> 5,000/mm3

6. Patients with pleural effusion

7. Patients with abnormal liver function: total bilirubin > 2.0 mg/dL

8. Patients with abnormal renal function: serum creatinine > 2.0 mg/dL

9. Patients who have received prior external beam radiation therapy to > 25% of active
bone marrow (involved field or regional)

10. Patients who have received G-CSF or GM-CSF therapy within two weeks prior to
treatment

11. Serious nonmalignant disease or infection which, in the opinion of the investigator
and/or the sponsor, would compromise other protocol objectives

12. Major surgery, other than diagnostic surgery, within four weeks